Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17441052 | 0.89 | IRAK4 (0.52) | IRAK4 | |
| SCHEMBL17449332 | 0.87 | IRAK4 (0.63) | IRAK4 | |
| SCHEMBL17441455 | 0.84 | IRAK4 (0.54) | IRAK4 | |
| SCHEMBL17441022 | 0.83 | IRAK4 (0.55) | IRAK4 | |
| SCHEMBL19130703 | 0.81 | IRAK4 (0.60) | IRAK4 | |
| SCHEMBL17449328 | 0.80 | IRAK4 (0.58) | IRAK4 | |
| SCHEMBL17441702 | 0.80 | IRAK4 (0.51) | IRAK4 | |
| SCHEMBL17441257 | 0.79 | IRAK4 (0.61) | IRAK4 | |
| SCHEMBL19124698 | 0.78 | IRAK4 (0.46) | IRAK4 | |
| SCHEMBL17441519 | 0.77 | IRAK4 (0.60) | IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577367-B2 | IRAK4 inhibiting agents | BIOGEN MA INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190248787-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. | 2019-08-15 | — | — | US | disclosed |
| US-10246456-B2 | IRAK4 inhibiting agents | BIOGEN MA INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-10246456-B2 | IRAK4 inhibiting agents | BIOGEN MA INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20170204093-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. | 2017-07-20 | — | — | US | disclosed |
| US-20170204093-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. | 2017-07-20 | — | — | US | disclosed |
| US-20170204093-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. | 2017-07-20 | — | — | US | disclosed |
| WO-2016011390-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| WO-2016011390-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. (US) | 2016-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246456-B2 | IRAK4 inhibiting agents | IRAK4, IRAK1, IRAK2 | IRAK4 1/4885SORT1 3303/4885 |
| US-20170204093-A1 | IRAK4 INHIBITING AGENTS | IRAK4, IRAK1, IRAK2 | IRAK4 1/4885SORT1 3303/4885 |
| US-20190248787-A1 | IRAK4 INHIBITING AGENTS | IRAK4, IRAK1, IRAK2 | IRAK4 1/4885SORT1 3130/4885 |
| US-10577367-B2 | IRAK4 inhibiting agents | IRAK4, IRAK1, IRAK2 | IRAK4 1/4885SORT1 3130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.